[HTML][HTML] Viral proteases as therapeutic targets
T Majerová, J Konvalinka - Molecular aspects of medicine, 2022 - Elsevier
Some medically important viruses―including retroviruses, flaviviruses, coronaviruses, and
herpesviruses―code for a protease, which is indispensable for viral maturation and …
herpesviruses―code for a protease, which is indispensable for viral maturation and …
Elesclomol, a copper-transporting therapeutic agent targeting mitochondria: from discovery to its novel applications
Copper (Cu) is an essential element that is involved in a variety of biochemical processes.
Both deficiency and accumulation of Cu are associated with various diseases; and a high …
Both deficiency and accumulation of Cu are associated with various diseases; and a high …
The impact of comorbidities and obesity on the severity and outcome of COVID-19 in hospitalized Patients—A retrospective study in a Hungarian hospital
É Nagy, V Cseh, I Barcs, E Ludwig - International Journal of …, 2023 - mdpi.com
Patients with comorbidities and obesity are more likely to be hospitalized with coronavirus
disease 2019 (COVID-19), to have a higher incidence of severe pneumonia and to also …
disease 2019 (COVID-19), to have a higher incidence of severe pneumonia and to also …
Analysis of all-cause hospitalization and death among nonhospitalized patients with type 2 diabetes and SARS-CoV-2 infection treated with molnupiravir or …
Importance Diabetes and COVID-19 are both global pandemics, and type 2 diabetes is a
common comorbidity in patients with acute COVID-19 and is proven to be a key determinant …
common comorbidity in patients with acute COVID-19 and is proven to be a key determinant …
[HTML][HTML] Exploring the future of SARS-CoV-2 treatment after the first two years of the pandemic: A comparative study of alternative therapeutics
BA Babalola, OS Akinsuyi, EO Folajimi, F Olujimi… - Biomedicine & …, 2023 - Elsevier
One of the most pressing challenges associated with SARS-CoV-2 treatment is the
emergence of new variants that may be more transmissible, cause more severe disease, or …
emergence of new variants that may be more transmissible, cause more severe disease, or …
The Efficacy of Multivitamin, Vitamin A, Vitamin B, Vitamin C, and Vitamin D Supplements in the Prevention and Management of COVID-19 and Long-COVID: An …
A Sinopoli, A Sciurti, C Isonne, MM Santoro… - Nutrients, 2024 - mdpi.com
This review aims to evaluate the efficacy of any vitamin administration (s) in preventing and
managing COVID-19 and/or long-COVID. Databases were searched up to May 2023 to …
managing COVID-19 and/or long-COVID. Databases were searched up to May 2023 to …
Pathogenesis and preventive tactics of immune-mediated non-pulmonary COVID-19 in children and beyond
H Chi, L Chang, YC Chao, DS Lin, HW Yang… - International Journal of …, 2022 - mdpi.com
The COVID-19 pandemic has evolved to immune escape and threatened small children and
the elderly with a higher severity and fatality of non-pulmonary diseases. These life …
the elderly with a higher severity and fatality of non-pulmonary diseases. These life …
Infliximab as a potential treatment for COVID-19
MP Velez, MW McCarthy - Expert Review of Anti-infective Therapy, 2023 - Taylor & Francis
Introduction As the third year of the SARS-CoV-2 pandemic approaches, COVID-19
continues to cause substantial morbidity and mortality due to waning vaccine efficacy and …
continues to cause substantial morbidity and mortality due to waning vaccine efficacy and …
[HTML][HTML] Efficacy and safety of oral antivirals in individuals aged 80 years or older with mild-to-moderate COVID-19: preliminary report from an Italian Prescriber Center
G Bruno, S Perelli, M Giotta, N Bartolomeo… - Le Infezioni in …, 2022 - ncbi.nlm.nih.gov
Methods All consecutive individuals aged≥ 80 years with confirmed COVID-19 and mild-to-
moderate illness who received an oral antiviral prescription between 11th January and 31 st …
moderate illness who received an oral antiviral prescription between 11th January and 31 st …
Effectiveness of the available early therapies in reducing severe COVID-19 in non-hospitalized patients with solid tumors on active treatment
A Lasagna, I Cassaniti, D Lilleri, M Quaccini… - Frontiers in …, 2022 - frontiersin.org
Emergency use authorization of drugs against severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) by regulatory authorities has provided new options to treat …
coronavirus 2 (SARS-CoV-2) by regulatory authorities has provided new options to treat …